Reprint
PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer
Edited by
July 2023
462 pages
- ISBN978-3-0365-8156-9 (Hardback)
- ISBN978-3-0365-8157-6 (PDF)
This book is a reprint of the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
This Special Issue of Cancers contains research and review articles on “PARPs, PAR and NAD metabolism and their inhibitors in Cancer”. It focuses on selected papers from the PARP2019 conference on “New Avenues in Basic and Translational PARP research”, that took place in Budapest (Hungary), on 20–23 May 2019.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
MDS; PARP inhibitors; olaparib; hematopoietic differentiation; PARP1; AML; poly-ADP-ribose polymerase 1 (PARP1); brahma-related gene 1 (BRG1); histone acetyltransferase p300 (EP300); gene transcription; cancer cell; head and neck squamous cell carcinoma; CAL27; SCC90; p60/p150 CAF-1 subunits; DNA repair; homologous recombination; biomarkers; personalized treatment; UVB; PARP; mitochondria; metabolism; biogenesis; autophagy; carcinogenesis; DNA repair; transcription; PARylation; PARP; DNA damage; transcription silencing; olaparib; carryover effect; TOP1 activity; TDP1; irinotecan; PARP; immunomodulation; tumor microenvironment; PARP; PARP inhibitors; PARylation; trapping; cancer therapeutic strategy; arginine-specific mono-ADP-ribosylation; bacterial toxin; cholera toxin; ART1; ARH1; tumorigenesis; loss of heterozygosity; membrane repair; gender bias; Syk; PARP; EGFR; squamous cell carcinoma; PARP-Akt interplay; PI3K; mTOR; cytoprotection; apoptosis resistance; oxidative stress; mitochondrial protection; PARP; drug development; synthetic lethality; clinical trials; ADP-ribosylation; cancer; macrodomain; ADP-ribosyl hydrolase; PARP; ARTD; MACROD1; MACROD2; TARG1; ATM; olaparib; ATR; PARP; PARP inhibitor; prostate cancer; pancreatic cancer; lung cancer; Tumor microenvironment; PARPs; PARylation; hypoxia; autophagy; PARP inhibitors; PARP; ATR; CHK1; replication stress; homologous recombination DNA repair; cell cycle; cytotoxicity; PARP Inhibitors; beta-lapachone; NQO1; PARG; NAMPT; cancer therapeutics; DNA repair; cMET; cancer; poly (ADP-ribose) glycohydrolase; radiosensitization; poly (ADP-ribose) polymerase; ES cells; poly (ADP-ribose) polymerase inhibitors (PARPi); ataxia telangiectasia and Rad3 related inhibitors (ATRi); replication stress; cell cycle checkpoints; NAD+; NMNAT1; cisplatin; chemotherapy; apoptosis; PARP1; osteosarcoma; cancer; PARP inhibitor; DNA damage response; immunotherapy; immune checkpoint inhibitor; PD-1; PD-L1; CTLA-4; combination therapy; solid tumors; the PARP inhibitor PJ34; distorted mitotic spindles; exclusive eradication of human cancer cells; nucleolus; poly(ADP-ribosyl)ation; PARP; ARTDs; cancer; n/a